ON2 Assessing the Performance of Landmark Response Analysis to Improve Overall Survival Extrapolation in Nivolumab NSCLC Trials
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.062
https://www.valueinhealthjournal.com/article/S1098-3015(20)32318-4/fulltext
Title :
ON2 Assessing the Performance of Landmark Response Analysis to Improve Overall Survival Extrapolation in Nivolumab NSCLC Trials
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32318-4&doi=10.1016/j.jval.2020.08.062
First page :
Section Title :
Open access? :
No
Section Order :
10039